康泰生物(300601.SZ):民海生物與大興區政府、阿斯利康舉行《戰略合作備忘錄》簽約儀式
格隆匯3月26日丨康泰生物(300601.SZ)公佈,公司全資子公司北京民海生物科技有限公司(簡稱“民海生物”)與北京市大興區人民政府(簡稱“大興區政府”)、阿斯利康投資(中國)有限公司(簡稱“阿斯利康”)於2024年3月25日舉行了《戰略合作備忘錄》簽約儀式。
根據國家法律法規規定並受限於各方內部批准,在充分協商的基礎上,各方願意共同探索建立戰略合作關係的機會,在以下領域逐步探索全方位合作:共同探索建立疫苗領域的長期戰略合作,探討互惠互利的合作模式,共同推動阿斯利康和民海生物雙方創新產品管線在中國的本地化和市場準入,具體合作範圍將根據協商和約定來確定。此舉旨在加速世界科學創新成果儘早惠及中國患者,同時促進海外先進疫苗生產管理技術的引進,推動中國醫療產業的發展,提升就業和經濟水平,助力中國疫苗創新產品海內外合作與發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.